DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

International Day of Radiology 2012 Homepage

The ISO Story Parts and service

Special report: Contrast injectors Injector integration will play a crucial role for future offerings.

Special report: Mobile C-arms Better dose management, image quality, workflow and integration.

Special report: Endoscopy, doing more for less Endoscopic devices and procedures lowering costs and improving outcomes.

Helium crisis averted? Rising prices may still be a sticking point.

Special report: MRI innovations are more personalized than ever Finding the right fit.

Special report: Competition heats up for parts providers So what's in it for you?

Special report: Cosmetic lasers sector takes a hit Are online discounts ruining the cosmetic laser market?

Special report: Ultrasound The technology is in the midst of a perfect storm.

Special report: Will molecular imaging deliver on its promises? Breakthroughs and challenges in the industry.

Special report: The end of traditional mammography?

by Carol Ko , Staff Writer
From the July 2013 issue of DOTmed HealthCare Business News magazine


Just now common are false positives? It depends on your definition. More than half of women who get mammograms in their forties can expect to get called back for additional screenings, though many doctors dispute whether this should count as a false positive.

It’s estimated that 7 to 9 percent of patients will receive a false-positive biopsy recommendation, while false positive results will send 10 out of 200 women to unnecessary surgery.
Story Continues Below Advertisement

Our products help save lives every single day

Getinge is a leading global provider of innovative solutions for operating rooms, intensive-care units, hospital wards, sterilization departments, elderly care and for life sciences companies and institutions. Click to read more




“One of the things about the risks of screening is patients get unnecessary biopsies and callbacks — better precision in imaging would help that,” says Dr. Julia White, professor of oncology at Ohio State University.

But there’s a tricky balance between lowering false positives while maintaining enough screening accuracy to avoid an uptick in false negatives. The challenge for screening technology is essentially twofold: screenings must be accurate enough to pick up on abnormalities while being sensitive enough to rule out misleading signs.

On the lab-error side, manufacturers have also devised products to help remedy the problem on a more practical level. The Know Error System, for example, is a DNA matching product that confirms that surgical biopsy samples being evaluated belong to the patient being diagnosed. Such safeguards may help put patients’ worries to rest as they go into surgery.

Dr. David Dorfman of Zwanger-Pesiri Radiology in New York says that the product has helped greatly enhance patient satisfaction at relatively low cost.

Along with the question of false positives, there’s also uncertainty around the issue of overtreatment. A one-size-fits-all treatment may be unnecessary, even outright harmful, depending on the kind of breast cancer screenings detect, according to experts. “Breast cancer is a very heterogeneous disease and has different risks and recurrence rates,” says Dr. John Nelson of Battlefield Imaging.

For example, a screening may turn up abnormalities such as DCIS—a kind of slow-growing cancer in the breast duct that usually never progresses to the point of killing a woman. If such abnormalities are found, it’s followed up with more tests, and if it’s found to be cancerous — even if it’s relatively harmless — women commonly have it treated with radiation, hormone therapy, chemotherapy, surgery, or even breast removal, all of which pose additional risks that may not be worth it if the cancer poses little mortality risk for the patient.

Dense Detection
One of the major limitations of mammography lies in its failure to adequately detect cancer in women with dense breasts, or breasts that have more connective tissue than fatty tissue. Approximately 40 percent of patients undergoing screenings have dense breasts.
<< Pages: 1 - 2 - 3 - 4 - 5 - 6 >>

International Day of Radiology 2012 Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED